32 and 3.78, respectively, P < 0.0001). Similarly, analysis of the SRTR between 1990 and 2005 demonstrated that recipients aged ≥70 years

receiving ECD or non-ECD deceased donor grafts had a 56% lower mortality risk compared with wait-listed dialysis patients aged ≥ 70 years (risk ratio (RR) 0.59; 95% confidence interval (CI) 0.53, 0.65; P < 0.0001), and this benefit persisted in elderly patients with diabetes and hypertension.5 As the unadjusted 1 year graft and death-censored graft survival of elderly transplant recipients were 81% and 90%, respectively; and were 67% and 85%, respectively, at 3 years, this suggested that a considerable proportion of these recipients die with functioning grafts. Other studies have demonstrated similar survival Selleckchem Ulixertinib benefit

in elderly recipients ≥60 years of ECD and non-ECD grafts compared with those remaining on the waiting list.20,21 A retrospective analysis of the Australia check details and New Zealand Dialysis and Transplant Registry (ANZDATA) of 4466 deceased donor transplants between 1991 and 2005 reported poorer outcomes in recipients of ECD grafts, compared with non-ECD grafts.10 Compared with non-ECD grafts, ECD grafts were associated with poorer graft function and a greater risk of DGF, acute rejection and death-censored graft failure. Although ECD grafts are associated with poorer outcomes compared with non-ECD grafts, the contribution of donor age, especially the upper acceptable age limit on graft outcomes among ECD grafts remains PRKACG unclear. The utilization of very old donors, defined as >75 years, has been steadily increasing in many countries including Italy (15%), but in Australia these donors accounted for only 3% of donors between 2007 and 2009.7 In a retrospective analysis of the United Network of Organ Sharing (UNOS) and Organ Procurement Transplant Network (OPTN) database, the impact of donor age on 9580 ECD renal grafts were examined.13 There was no association between donor age and acute rejection, although ECD transplants from donors aged ≥70 years had poorer function at 12 months

compared with grafts from younger ECD donors. In an adjusted model, ECD transplants from donors aged ≥70 years were associated with an increased risk of graft failure and patient death compared with ECD transplants from donors aged 50–69 years (hazard ratio (HR) 1.37 and 1.37, respectively, P < 0.01). When stratified by recipient age, ECD transplants from donors aged ≥70 years (compared with ECD 50–69 years) were associated with an increased risk of death-censored graft loss for recipients aged 41–60 years (HR 1.48, 95% CI 1.06, 2.06; P = 0.02) but not for older recipients aged > 60 years (HR 1.12, 95% CI 0.86, 1.46; P = 0.40), suggesting that older ECD grafts may have a lesser adverse impact in older recipients. Furthermore, among younger recipients, those with older ECD grafts had a 50% greater risk of returning to dialysis, whereas in older recipients, this association was not observed.